Tracers / [99mTc]N4-CCK-100
[99mTc]N4-CCK-100
Also written as [Tc-99m]Tc-N4-CCK-100
- Radionuclide
- Tc-99m t½ 360.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- CCK-2 receptor-targeted peptide (N4-chelator conjugated)
- Target / mechanism
- Cholecystokinin-2 receptor (CCK-2R) PMID 42477299
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | >99% | 87.7-94.0% | N4-CCK-100 | 42477299 2026 EJNMMI Radiopharm Chem The labeling solution was incubated at 95 °C for 15 min. — 99mTc-Labeling afforded [99mTc]Tc-N4-CCK-66 and [99mTc]Tc-N4-CCK-100 to -105 ([99mTc]Tc-11 to -17) in quantitative radiochemical yields (RCY > 99%) |
Need this precursor?We can point you to suppliers for [99mTc]N4-CCK-100, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 42477299. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 42477299: 'N4-CCK-100 to -105 (12–17)'. Stage set/updated at stage 23 from PMID 42477299: 'Synthesis and in vitro evaluation of pharmacokinetically optimized 99mTc-labeled cholecystokinin-2 receptor-targeted peptides for improved SPECT imaging.'.